Matching articles for "Tzield"
Issue 1757 · June 22, 2026 Free
In Brief: An Expanded Indication for Teplizumab (Tzield)

The CD3-directed monoclonal antibody teplizumab ( Tzield – Provention Bio), which was previously approved by the FDA to delay the onset of stage 3 type 1 diabetes in patients ≥8 years old with stage 2 type…

Med Lett Drugs Ther. 2026 Jun 22; 68(1757):100-1 doi:10.58347/tml.2026.1757c
The CD3-directed monoclonal antibody teplizumab ( Tzield – Provention Bio), which was previously approved by the FDA to delay the onset of stage 3 type 1 diabetes in patients ≥8 years old with stage 2 type 1 diabetes, has now been approved for such use in children 1-7 years old.
Issue 1667 · January 9, 2023
Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes

Teplizumab-mzwv ( Tzield – Provention Bio), an anti-CD3 monoclonal antibody, has been approved by the FDA to delay the onset of stage 3 type 1 diabetes in patients ≥8 years old who have stage 2 type 1…

Med Lett Drugs Ther. 2023 Jan 9; 65(1667):7-8 doi:10.58347/tml.2023.1667c
Teplizumab-mzwv ( Tzield – Provention Bio), an anti-CD3 monoclonal antibody, has been approved by the FDA to delay the onset of stage 3 type 1 diabetes in patients ≥8 years old who have stage 2 type 1 diabetes. It is the first drug to become available in the US that delays the onset of type 1 diabetes.